Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

As the genetic testing company 23andMe prepares for a potential sale, Congress is ramping up its scrutiny on how the company handles data privacy concerns.

Lawmakers have sent a letter to 23andMe’s CEO requesting information on how the company collects, stores, and shares genetic data from its users.

There are growing concerns over the potential misuse of sensitive genetic information by third parties, especially in the realm of healthcare and insurance.

Congress is demanding transparency from 23andMe on how it plans to protect user data in the event of a sale or acquisition.

Privacy advocates are also calling for stronger regulations to safeguard genetic data and ensure that individuals have control over how their information is used.

The sale of 23andMe raises important questions about the future of genetic data privacy and the need for tighter controls on how companies handle such sensitive information.

As the debate over data privacy continues to heat up, it is clear that lawmakers are determined to hold companies like 23andMe accountable for how they handle user data.

It remains to be seen how 23andMe will respond to Congress’s demands for answers on data privacy, but the outcome could have far-reaching implications for the industry as a whole.

For now, the spotlight is on 23andMe as lawmakers and privacy advocates push for greater transparency and accountability in the handling of genetic data.

Only time will tell how this growing scrutiny will impact the broader conversation around data privacy and the protection of personal information in the digital age.